Table 6 Associations between NEDD4–1 and NRDP1 protein expression and clinicopathological characteristics in HER2-amplified breast cancer cohort
Characteristic | Cytoplasmic NRDP1 expression n (%) | Nuclear NRDP1 expression n (%) | Cellular NEDD4–1 expression n (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
n | NRDP1- | NRDP1+ | p | NRDP1- | NRDP1+ | p | NEDD4–1- | NEDD4–1+ | p | |
Cases | 145 | 133 (91.7) | 12 (8.3) | 133 (91.7) | 12 (8.3) | 25 (17.2) | 120 (82.8) | |||
Estrogen receptor | 0.057 | 0.206 | 0.421 | |||||||
Positive | 97 | 86 (64.7) | 11 (91.7) | 87 (65.4) | 10 (83.3) | 15 (60.0) | 82 (68.3) | |||
Negative | 48 | 47 (35.3) | 1 (8.3) | 46 (34.6) | 2 (16.7) | 10 (40.0) | 38 (31.7) | |||
Progesterone receptor | 0.006** | 0.125 | 0.053 | |||||||
Positive | 66 | 56 (42.1) | 10 (83.3) | 58 (43.6) | 8 (66.7) | 7 (28.0) | 59 (49.2) | |||
Negative | 79 | 77 (57.9) | 2 (16.7) | 75 (56.4) | 4 (33.3) | 18 (72.0) | 61 (50.8) | |||
Histological grade | 0.953 | 0.446 | 0.134 | |||||||
I-II | 35 | 32 (24.2) | 3 (25.0) | 31 (23.5) | 4 (33.3) | 9 (36.0) | 26 (21.8) | |||
III | 109 | 100 (75.8) | 9 (75.0) | 101 (76.5) | 8 (66.7) | 16 (64.0) | 93 (78.2) | |||
Ki-67 proliferation index | 0.228 | 0.228 | 1.000 | |||||||
Low | 29 | 25 (18.8) | 4 (33.3) | 25 (18.8) | 4 (33.3) | 5 (25.0) | 24 (20.0) | |||
High | 116 | 108 (81.2) | 8 (66.7) | 108 (81.2) | 8 (66.7) | 20 (75.0) | 96 (80.0) | |||
Histological type | 0.022* | 0.880 | 0.403 | |||||||
Ductal | 128 | 119 (93.7) | 9 (75.0) | 118 (92.2) | 10 (90.9) | 22 (88.0) | 106 (93.0) | |||
Lobular | 11 | 8 (6.3) | 3 (25.0) | 10 (7.8) | 1 (9.1) | 3 (12.0) | 8 (7.0) | |||
Lymph nodal status | 0.120 | 0.277 | 0.516 | |||||||
Positive pN+ | 60 | 58 (45.3) | 2 (20.0) | 53 (42.1) | 7 (58.3) | 9 (37.5) | 51 (44.7) | |||
Negative pN0 | 78 | 70 (54.7) | 8 (80.0) | 73 (57.9) | 5 (41.7) | 15 (62.5) | 63 (55.3) | |||
Tumor size (cm) | 0.669 | 0.820 | 0.715 | |||||||
< 2 cm | 57 | 52 (48.1) | 5 (55.6) | 52 (49.1) | 5 (45.5) | 9 (45.0) | 48 (49.5) | |||
≥ 2 cm | 60 | 56 (51.9) | 4 (44.4) | 54 (50.9) | 6 (54.5) | 11 (55.0) | 49 (50.5) | |||
Tumor size (TNM stage) | 0.511 | 0.341 | 0.177 | |||||||
pT1-pT2 | 138 | 127 (96.2) | 11 (100.0) | 127 (96.9) | 11 (91.7) | 23 (92.0) | 115 (97.5) | |||
pT3-pT4 | 5 | 5 (3.8) | 0 (0.0) | 4 (3.1) | 1 (8.3) | 2 (8.0) | 3 (2.5) | |||
Patient age at diagnosis | 0.856 | 0.004** | 0.771 | |||||||
< 50 years | 27 | 25 (18.8) | 2 (16.7) | 21 (15.8) | 6 (50.0) | 4 (16.0) | 23 (19.2) | |||
≥ 50 years | 118 | 108 (81.2) | 10 (83.3) | 112 (84.2) | 6 (50.0) | 21 (84.0) | 97 (80.8) | |||
HER3 membrane expression | 0.905 | 0.505 | 0.002** | |||||||
Low | 26 | 24 (18.0) | 2 (16.7) | 23 (17.3) | 3 (25.0) | 10 (40.0) | 16 (13.3) | |||
High | 119 | 109 (82.0) | 10 (83.3) | 110 (82.7) | 9 (75.0) | 15 (60.0) | 104 (86.7) | |||
HER3 cytoplasmic expression | 0.300 | 0.215 | 0.360 | |||||||
Low | 11 | 11 (8.3) | 0 (0.0) | 9 (6.8) | 2 (16.7) | 3 (12.0) | 8 (6.7) | |||
High | 134 | 122 (91.7) | 12 (100.0) | 124 (93.2) | 10 (83.3) | 22 (88.0) | 112 (93.3) | |||
HER3 total cellular expression | 0.041* | 0.942 | 0.620 | |||||||
Low | 35 | 35 (26.3) | 0 (0.0) | 32 (24.1) | 3 (25.0) | 7 (28.0) | 28 (23.3) | |||
High | 110 | 98 (73.7) | 12 (100.0) | 101 (75.9) | 9 (75.0) | 18 (72.0) | 92 (76.7) | |||
Cytokeratin 5/14 expression | 0.199 | 0.199 | 0.578 | |||||||
Negative | 127 | 115 (87.8) | 12 (100.0) | 115 (87.8) | 12 (100.0) | 23 (92.0) | 104 (88.1) | |||
Positive | 16 | 16 (12.2) | 0 (0.0) | 16 (12.2) | 0 (0.0) | 2 (8.0) | 14 (11.9) | |||